SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. announced today it has initiated a second Phase I clinical trial of KD7040, a topical inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The company completed a single dose-escalation study in March of this year and expects to compete a multiple dose-escalation study around mid-2007 (N= approximately 50). Together the studies will evaluate the safety, tolerability and pharmacokinetics of KD7040 versus placebo in healthy volunteers.
